Alamar Biosciences, Inc. (ALMR)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Alamar Biosciences: Promising But Expensive Proteomics Growth
Alamar Biosciences' ARGO instruments automate NULISA assays. This creates a platform that can convert placements into recurring consumables' demand. I concede that ALMR's broader disease panels and sampling could also deepen the utilization of its platform and expand its long-term TAM even into diagnostics. The good news is that consumables are growing faster than instruments. But we need to see if this will be long-term profitable growth as the installed base expands.
Alamar Biosciences Q2 Earnings Call Highlights
Alamar Biosciences NASDAQ: ALMR reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company's first earnings call since completing its April initial public offering.
